NCT00141583

Brief Summary

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Apr 2004

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

August 31, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 1, 2005

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2006

Completed
Last Updated

June 9, 2015

Status Verified

May 1, 2007

First QC Date

August 31, 2005

Last Update Submit

June 5, 2015

Conditions

Hypertension

Keywords

Renin-angiotensin systemACE InhibitorAngiotensin Receptor Blocker

Outcome Measures

Primary Outcomes (2)

  • Change in BP

  • Change in PRA and aldosterone

Interventions

Enalapril 20 mg bdDRUG
Candesartan 8 mg bdDRUG

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Essential Hypertension
  • SBP 140-159 mmHg
  • DBP 90-99 mmHg

You may not qualify if:

  • Intolerance of or allergy to ACE Inhibitors or ARBS
  • Pregnant or Breastfeeding
  • Pre-menopausal women
  • Uncontrolled cardiac or renal failure
  • Diabetes mellitus

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL

London, SW17 0RE, United Kingdom

Location

MeSH Terms

Conditions

Hypertension

Interventions

Enalaprilcandesartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

DipeptidesOligopeptidesPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Timothy WR Doulton, BSc MRCP

    SGUL

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 31, 2005

First Posted

September 1, 2005

Study Start

April 1, 2004

Study Completion

October 1, 2006

Last Updated

June 9, 2015

Record last verified: 2007-05

Locations

GB(1)